Abstract
In 1960 Ph-chromosome was found associated with the presence of chronic myelogenous leukemia. In these 50 years an increasing number of cytogenetic abnormalities have been found associated with hematological malignancies. The presence of these abnormalities is not only important for the diagnosis of the patient, but it also contributes to the prognosis of patients with leukemia or lymphoma. For this reason the WHO classification of hematological disease has included these studies for the correct characterization of leukemias and lymphomas. In addition, the use of FISH and micromatrix methodologies have refined the genetic lesions present in these malignancies. The cytogenetic changes observed also provide further information in relation to the therapy.
Copyright © 2010 Elsevier España, S.L. All rights reserved.
Publication types
-
English Abstract
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Aneuploidy
-
Biomarkers, Tumor
-
Chromosome Aberrations
-
Chromosomes, Human / genetics
-
Chromosomes, Human / ultrastructure
-
Comparative Genomic Hybridization
-
Cytogenetics / methods*
-
Cytogenetics / trends
-
Fusion Proteins, bcr-abl / analysis
-
Fusion Proteins, bcr-abl / genetics
-
Hematologic Neoplasms / classification
-
Hematologic Neoplasms / genetics
-
Humans
-
In Situ Hybridization, Fluorescence
-
Karyotyping / methods
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Lymphoproliferative Disorders / genetics
-
Lymphoproliferative Disorders / pathology
-
Myelodysplastic Syndromes / genetics
-
Myelodysplastic Syndromes / pathology
-
Myeloproliferative Disorders / genetics
-
Myeloproliferative Disorders / pathology
-
Oligonucleotide Array Sequence Analysis*
-
Philadelphia Chromosome*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
-
World Health Organization
Substances
-
Biomarkers, Tumor
-
Fusion Proteins, bcr-abl